FMA
CARM

FNY Managed Accounts’s Carisma Therapeutics CARM Stock Holding History

FNY Managed Accounts’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-165
Closed -$29.4K – 488
2015
Q1 		$29.4K Buy
+165
New +$36K 0.02% 165

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

FNY Managed Accounts's CARM Position: Q2 2015 in Review

FNY Managed Accounts sold out of Carisma Therapeutics (CARM) in Q2 2015, closing a stake of 165 shares — an estimated $29.4K sold.

FNY Managed Accounts first reported a position in CARM in Q1 2015 and held it in 1 quarter. The position peaked at $29.4K in Q1 2015. 41 funds tracked by Wall St. Rank hold CARM as of Q2 2015.

  • FNY Managed Accounts reported no remaining Carisma Therapeutics position as of Q2 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 165 Carisma Therapeutics shares in Q2 2015, an estimated $29.4K.
  • FNY Managed Accounts first reported a position in Carisma Therapeutics in Q1 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Carisma Therapeutics position peaked at $29.4K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2015.

Based on FNY Managed Accounts's 13F filing for Q2 2015, filed 30 Jul 2015.